- TNF Inhibitors
- Interleukins
- Others
Psoriasis Treatment Market size was valued at USD 2,746.6 million in 2023 and is expected to grow at an 8.2% CAGR from 2024 to 2030. Psoriasis is an autoimmune inflammatory disorder, resulting from the rapid overgrowth of skin cells causing itchiness resulting in inflammation, red lesions, and plaque formation. The increasing prevalence of plaque and psoriatic arthritis, the increasing geriatric population, and the presence of huge pipeline drugs in the market are the key driving factors in the psoriasis treatment market. For instance, according to U.S. census data, the number of psoriasis cases reported is approximately 7.55 million in 2020.
In addition, the rising investments in research and development of biologics and biological therapy by the key market players are expected to fuel the market growth over the forecasted years. For instance, in April 2019, Novartis AG announced that the China Health Authority NMPA approved their product Cosentyx, first in class interleukin 17A inhibitors used to treat moderate to severe plaque psoriasis in adults. However, the high medication cost and lack of reimbursement policies in emerging countries and patients hesitant to visit dermatology for psoriasis treatment are expected to hinder the growth of the psoriasis treatment market over the forecasted years. For instance, according to the economic analysis of psoriasis treatment, the proportion of medication cost is 20% of the total cost. It was estimated that one in three patients face trouble paying for the cost of treatment. Furthermore, the market key players are involved in adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share which is expected to drive the psoriasis treatment market at a significant rate over the forecasted period.
Psoriasis Treatment Market Key Developments:
- In November 2021, AbbVie Inc. got the approval for SKYRIZI subcutaneous injection to treat active psoriatic arthritis from the European Commission.
- In September 2021, LEO Pharma A/S announced the partnership with Veeva Systems to continue clinical trials with high significance.
Global Psoriasis Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8.2%
Largest Market
North America
Fastest Growing Market
North America
Psoriasis Treatment Market Dynamics
Psoriasis treatment market is expected to grow over the forecasted period due to the increasing prevalence of plaque psoriasis and psoriatic arthritis and increasing geriatric population across the globe. In addition, the growing usage of combined therapy for the treatment of psoriasis and approval of psoriasis drugs across the globe is expected to boost the market growth. furthermore, the development of cutting-edge technology, raising awareness of treatment and growing research and development for psoriasis treatment are expected to fuel the market growth over the forecasted period. On the other side, the high cost of treatment is expected to hinder the market growth.
North-America Got Significant Share
Psoriasis Treatment Market Regional Analysis
Psoriasis treatment market is segmented based on regions into North America, Asia-pacific, Europe, Latin America and Middle East and Africa. North America psoriasis treatment market is likely to hold a significant revenue share, and in the forecasted years, it is predicted to increase rapidly due to the increasing prevalence of psoriasis disease and increase in demand for psoriasis medicines and upsurge in the research and pipeline drugs. Europe Psoriasis market is anticipated to have second largest market share due to the increasing demand for psoriasis treatment in this region. Asia Pacific region is also expected to have a significant growth due to the raising awareness of psoriasis illness and its treatment.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Psoriasis Treatment Market Segmentation
By Drug class
By Type
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
By Route-administration
- Oral
- Parenteral
- Topical
By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Frequently Asked Questions
The psoriasis treatment market is projected to expand at a CAGR of 8.2% during the forecast period
Amgen Inc. (U.S), Eli Lilly and Company(U.S), Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc., (U.S), Pfizer, Inc. (U.S), AstraZeneca (U.K)
North America is the fastest-growing region for psoriasis treatment market
Increasing prevalence of plaque psoriasis and psoriatic arthritis and innovation of new pipeline drugs are expected to drive the growth of psoriasis treatment market over the forecasted years.
| 1. Executive Summary |
| 2. Global Psoriasis Treatment Market Introduction |
| 2.1. Global Psoriasis Treatment Market – Taxonomy |
| 2.2. Global Psoriasis Treatment Market – Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Psoriasis Type |
| 2.2.3. By Route of Administration |
| 2.2.4. By Distribution Channel |
| 2.2.5. By Region |
| 3. Global Psoriasis Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Psoriasis Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Psoriasis Treatment Market – Competition Landscape |
| 4. Global Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Psoriasis Treatment Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. TNF Inhibitors |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Vitamin D Analogues |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Interleukin Blockers |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Topical Corticosteroids |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Monoclonal Antibodies |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Psoriasis Treatment Market, By Psoriasis Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Plaque Psoriasis |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Guttate Psoriasis |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Flexural Psoriasis |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Inverse Psoriasis |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Psoriatic Psoriasis |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Psoriasis Treatment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Topical |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Parenteral |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Psoriasis Treatment Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Psoriasis Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, By Route of Administration, By Distribution Channel, and Region, 2024 - 2030 |
| 10. North America Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. TNF Inhibitors |
| 10.1.2. Vitamin D Analogues |
| 10.1.3. Interleukin Blockers |
| 10.1.4. Topical Corticosteroids |
| 10.1.5. Monoclonal Antibodies |
| 10.1.6. Others |
| 10.2. Psoriasis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Plaque Psoriasis |
| 10.2.2. Guttate Psoriasis |
| 10.2.3. Flexural Psoriasis |
| 10.2.4. Inverse Psoriasis |
| 10.2.5. Psoriatic Psoriasis |
| 10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Oral |
| 10.3.2. Topical |
| 10.3.3. Parenteral |
| 10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Hospital Pharmacies |
| 10.4.2. Retail Pharmacies |
| 10.4.3. Online Pharmacies |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. USA |
| 10.5.2. Canada |
| 10.6. North America Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030 |
| 10.7. North America Psoriasis Treatment Market Dynamics – Trends |
| 11. Europe Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. TNF Inhibitors |
| 11.1.2. Vitamin D Analogues |
| 11.1.3. Interleukin Blockers |
| 11.1.4. Topical Corticosteroids |
| 11.1.5. Monoclonal Antibodies |
| 11.1.6. Others |
| 11.2. Psoriasis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Plaque Psoriasis |
| 11.2.2. Guttate Psoriasis |
| 11.2.3. Flexural Psoriasis |
| 11.2.4. Inverse Psoriasis |
| 11.2.5. Psoriatic Psoriasis |
| 11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Oral |
| 11.3.2. Topical |
| 11.3.3. Parenteral |
| 11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Hospital Pharmacies |
| 11.4.2. Retail Pharmacies |
| 11.4.3. Online Pharmacies |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Spain |
| 11.5.5. Italy |
| 11.5.6. Russia |
| 11.5.7. Rest of Europe |
| 11.6. Europe Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030 |
| 11.7. Europe Psoriasis Treatment Market Dynamics – Trends |
| 12. Asia-Pacific Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. TNF Inhibitors |
| 12.1.2. Vitamin D Analogues |
| 12.1.3. Interleukin Blockers |
| 12.1.4. Topical Corticosteroids |
| 12.1.5. Monoclonal Antibodies |
| 12.1.6. Others |
| 12.2. Psoriasis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Plaque Psoriasis |
| 12.2.2. Guttate Psoriasis |
| 12.2.3. Flexural Psoriasis |
| 12.2.4. Inverse Psoriasis |
| 12.2.5. Psoriatic Psoriasis |
| 12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Oral |
| 12.3.2. Topical |
| 12.3.3. Parenteral |
| 12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Hospital Pharmacies |
| 12.4.2. Retail Pharmacies |
| 12.4.3. Online Pharmacies |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. China |
| 12.5.2. India |
| 12.5.3. Japan |
| 12.5.4. ASEAN |
| 12.5.5. Australia & New Zealand |
| 12.5.6. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, by Drug Class, By Distribution Channel, and Country, 2024 - 2030 |
| 12.7. Asia-Pacific Psoriasis Treatment Market Dynamics – Trends |
| 13. Latin America Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 13.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. TNF Inhibitors |
| 13.1.2. Vitamin D Analogues |
| 13.1.3. Interleukin Blockers |
| 13.1.4. Topical Corticosteroids |
| 13.1.5. Monoclonal Antibodies |
| 13.1.6. Others |
| 13.2. Psoriasis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Plaque Psoriasis |
| 13.2.2. Guttate Psoriasis |
| 13.2.3. Flexural Psoriasis |
| 13.2.4. Inverse Psoriasis |
| 13.2.5. Psoriatic Psoriasis |
| 13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Oral |
| 13.3.2. Topical |
| 13.3.3. Parenteral |
| 13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Hospital Pharmacies |
| 13.4.2. Retail Pharmacies |
| 13.4.3. Online Pharmacies |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030 |
| 13.7. Latin America Psoriasis Treatment Market Dynamics – Trends |
| 14. Middle East and Africa Psoriasis Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 14.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. TNF Inhibitors |
| 14.1.2. Vitamin D Analogues |
| 14.1.3. Interleukin Blockers |
| 14.1.4. Topical Corticosteroids |
| 14.1.5. Monoclonal Antibodies |
| 14.1.6. Others |
| 14.2. Psoriasis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Plaque Psoriasis |
| 14.2.2. Guttate Psoriasis |
| 14.2.3. Flexural Psoriasis |
| 14.2.4. Inverse Psoriasis |
| 14.2.5. Psoriatic Psoriasis |
| 14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Oral |
| 14.3.2. Topical |
| 14.3.3. Parenteral |
| 14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Hospital Pharmacies |
| 14.4.2. Retail Pharmacies |
| 14.4.3. Online Pharmacies |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Gulf CoDistribution Channel Council (GCC) Countries |
| 14.5.2. South Africa |
| 14.5.3. Rest of MEA |
| 14.6. MEA Psoriasis Treatment Market - Opportunity Analysis Index, By Drug Class, By Psoriasis Type, By Route of Administration, By Distribution Channel, and Country, 2024 - 2030 |
| 14.7. MEA Psoriasis Treatment Market Dynamics – Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Key Products, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Amgen Inc. (U.S) |
| 15.2.2. Eli Lilly and Company (U.S) |
| 15.2.3. Novartis AG (Switzerland) |
| 15.2.4. Merck & Co., Inc. (U.S) |
| 15.2.5. Johnson & Johnson Services, Inc., (U.S) |
| 15.2.6. Pfizer, Inc. (U.S) |
| 15.2.7. AstraZeneca (U.K) |
| 15.2.8. AbbVie Inc. (U.S) |
| 15.2.9. LEO Pharma A/S (Denmark) |
| 15.2.10. Biogen (U.S) |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Amgen Inc. (U.S)
- Eli Lilly and Company(U.S)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S)
- Johnson & Johnson Services, Inc., (U.S)
- Pfizer, Inc. (U.S)
- AstraZeneca (U.K)
- AbbVie Inc. (U.S)
- LEO Pharma A/S (Denmark)
- Biogen (U.S)